In the Journals

Evidence lacking for low FODMAP diet as treatment for IBS

Data supporting the low FODMAP diet for the treatment of irritable bowel syndrome is “very limited,” and caution should be used when recommending it to patients, according to a recently published review.

Developed in Australia and advocated in recent years for the treatment of IBS, the low FODMAP diet is low in poorly absorbed short-chain carbohydrates (fermentable oligosaccharides, disaccharides, monosaccharaides and polyols). According to the review, the diet is thought to be effective as undigested FODMAPS increase intestinal water volume and are quickly fermented; the resulting hydrogen, methane and carbon dioxide increases luminal distension, which may result in pain, bloating and changes in intestinal motility.

Efficacy evidence is limited to “a few relatively small, short-term unblinded or single-blinded controlled trials of varying duration,” the review said, though all show some evidence of improved symptoms with few adverse events.

Two recent review articles analyzing some of the same data had conflicting conclusions; one concluded there is “high quality evidence” supporting the efficacy of low FODMAP diet for IBS, whereas the other “was more cautious in its conclusion.”

A controlled trial not analyzed in either of these reviews demonstrated a significant improvement in IBS symptoms after 6 weeks of either low FODMAP diet or probiotic supplementation compared with a normal Danish diet (P < .01).

Another trial demonstrated low FODMAP diet was associated with lower numbers of bifidobacteria, though the clinical implications of the diet’s impact on gut microbiota are unclear.

None of the randomized trials reviewed exceeded a 6 week study period, so long-term effects of low FODMAP diet are unknown.

Three UK society guidelines were also included in the review and suggest the diet may be appropriate for some patients, but stipulate that advising should be provided by a health care professional with expertise in this kind of dietary management.

The authors concluded they “believe that patients should be advised that there is very limited evidence for” treating IBS symptoms with a low FODMAP diet. “The ideal duration of treatment has not been assessed in a clinical trial and its place in the management of IBS has not been fully established.” – by Adam Leitenberger

Disclosure: The researchers report no relevant financial disclosures.   

Data supporting the low FODMAP diet for the treatment of irritable bowel syndrome is “very limited,” and caution should be used when recommending it to patients, according to a recently published review.

Developed in Australia and advocated in recent years for the treatment of IBS, the low FODMAP diet is low in poorly absorbed short-chain carbohydrates (fermentable oligosaccharides, disaccharides, monosaccharaides and polyols). According to the review, the diet is thought to be effective as undigested FODMAPS increase intestinal water volume and are quickly fermented; the resulting hydrogen, methane and carbon dioxide increases luminal distension, which may result in pain, bloating and changes in intestinal motility.

Efficacy evidence is limited to “a few relatively small, short-term unblinded or single-blinded controlled trials of varying duration,” the review said, though all show some evidence of improved symptoms with few adverse events.

Two recent review articles analyzing some of the same data had conflicting conclusions; one concluded there is “high quality evidence” supporting the efficacy of low FODMAP diet for IBS, whereas the other “was more cautious in its conclusion.”

A controlled trial not analyzed in either of these reviews demonstrated a significant improvement in IBS symptoms after 6 weeks of either low FODMAP diet or probiotic supplementation compared with a normal Danish diet (P < .01).

Another trial demonstrated low FODMAP diet was associated with lower numbers of bifidobacteria, though the clinical implications of the diet’s impact on gut microbiota are unclear.

None of the randomized trials reviewed exceeded a 6 week study period, so long-term effects of low FODMAP diet are unknown.

Three UK society guidelines were also included in the review and suggest the diet may be appropriate for some patients, but stipulate that advising should be provided by a health care professional with expertise in this kind of dietary management.

The authors concluded they “believe that patients should be advised that there is very limited evidence for” treating IBS symptoms with a low FODMAP diet. “The ideal duration of treatment has not been assessed in a clinical trial and its place in the management of IBS has not been fully established.” – by Adam Leitenberger

Disclosure: The researchers report no relevant financial disclosures.